Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06619236 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorFinal enrollment: 584 participants (planned 530)Primary completion date changed from estimate of Feb 2027 to Aug 18, 2026 · Completion moved earlier from May 23, 2028 to Oct 2027 · Eligibility criteria expanded, about 20 words · 2 moreShow 5 more changesShow less
Primary completion date changed from estimate of Feb 2027 to Aug 18, 2026
Completion moved earlier from May 23, 2028 to Oct 2027
Eligibility criteria expanded, about 20 words
Secondary endpoints: details revised at 2 of 10 entries
Site details revised at 16 of 177 sites
MinorSite details revised at 3 of 177 sitesv25
MinorSecondary endpoints: 11 to 10Site details revised at 2 of 177 sitesv24Show 1 more changeShow less
MinorTrial status: Recruiting to Active, Not RecruitingStudy sites: 175 to 177v17Show 1 more changeShow less
Study sites: 175 to 177
MinorStudy sites: 173 to 175v16
MinorStudy sites: 162 to 173v15
MinorStudy sites: 144 to 162v14
MinorStudy sites: 83 to 144v13
MinorRe-verified, no change to tracked fieldsv12
MinorStudy sites: 68 to 83Primary completion date: May 2, 2027 to Feb 2027 · Completion date: Apr 5, 2028 to May 23, 2028 · Secondary endpoints: details revised at 10 of 11 entries · 1 morev11Show 4 more changesShow less
Primary completion date: May 2, 2027 to Feb 2027
Completion date: Apr 5, 2028 to May 23, 2028
Secondary endpoints: details revised at 10 of 11 entries
MinorStudy sites: 2 to 4Start date changed from estimate of Feb 2025 to Feb 7, 2025v6Show 1 more changeShow less
Start date changed from estimate of Feb 2025 to Feb 7, 2025
NotableTrial status: Not Yet Recruiting to RecruitingSite details revised at 2 of 2 sitesv5Show 1 more changeShow less
Site details revised at 2 of 2 sites
NotableStart date: Dec 15, 2024 to Feb 2025Study sites: 0 to 2 · Primary completion date: Feb 2027 to May 2, 2027 · Completion date: Nov 30, 2029 to Apr 5, 2028 · 2 morev4Show 5 more changesShow less
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase 3 study will be conducted in different countries all over the world.
The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer.
Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose.
All participants will receive active drug; no one will be given placebo.